Comparison
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980 vs 12q14 Microdeletion Syndrome C4305140
Clinical comparison between 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete CN042980 and 12q14 Microdeletion Syndrome for differential diagnosis and treatment planning.
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
A rare enzyme deficiency affecting hormone production, leading to low sex hormones and elevated blood pressure. Lifelong hormone replacement therapy is typically needed. Ongoing medical monitoring helps manage associated health concerns.
12q14 Microdeletion Syndrome C4305140
A rare genetic deletion involving a segment of chromosome 12. It may lead to developmental delays, learning difficulties, and other health issues. Management is individualized and focuses on supportive therapies.
6 comparison axes
Onset
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
0-null
12q14 Microdeletion Syndrome C4305140
0-2
Onset patterns differ
Severity
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
severe
12q14 Microdeletion Syndrome C4305140
moderate
Different severity levels
Chronic
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
Chronic
12q14 Microdeletion Syndrome C4305140
Chronic
Differing course
Communicable
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
No
12q14 Microdeletion Syndrome C4305140
No
Different transmission
Body System
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
endocrine
12q14 Microdeletion Syndrome C4305140
congenital
Same/different system
Category
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
endocrine
12q14 Microdeletion Syndrome C4305140
genetic
Different category
Bottom line
17-alpha-hydroxylase-17-20-lyase-deficiency-combined-complete-CN042980 and 12q14-microdeletion-syndrome-C4305140 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980 | 12q14 Microdeletion Syndrome C4305140 | Discriminating power |
|---|---|---|---|
| Blood pressure | Hypertension is a recognized concern from altered adrenal steroid balance. | Hypertension is not described as a defining feature. | High |
| Sex-hormone effects | Low sex hormones and disordered pubertal development are central concerns. | Not primarily a sex-hormone disorder based on supplied data. | High |
| Development and learning | Developmental delay is not the core described presentation. | Developmental delay and learning difficulty may occur. | Moderate |
When to favor each condition
Choose 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980 when
Hypertension with suspected low sex hormones
This pattern better matches the described endocrine enzyme deficiency.
Moderate
Suspected adrenal steroid biosynthesis disorder
Endocrine pathway evaluation is more relevant than deletion testing alone.
Moderate
Planning long-term hormone care
Source data indicate typical lifelong replacement and monitoring.
Moderate
Choose 12q14 Microdeletion Syndrome C4305140 when
Early developmental or learning concerns
These features align more closely with the described microdeletion.
Moderate
Suspected chromosomal copy-number change
Genetic deletion testing is the appropriate diagnostic direction.
Moderate
Need for supportive developmental care
Management is described as individualized and supportive.
Moderate
How key tests differ
| Test | 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980 | 12q14 Microdeletion Syndrome C4305140 | Interpretation |
|---|---|---|---|
| Adrenal steroid and electrolyte evaluation | May show abnormal steroid pattern; exact cutoffs are not established here. | No characteristic adrenal steroid abnormality is described. | An abnormal result supports endocrine assessment but is not itself a diagnosis. |
| Sex-hormone assessment | Low sex hormones may be found; interpretation depends on age and context. | Not expected to be the primary abnormality from supplied data. | Results must be interpreted by a clinician and not used alone. |
| Chromosomal microarray | Not the test that defines this enzyme deficiency. | May identify a 12q14 deletion when clinically indicated. | A genetic result requires laboratory and clinical confirmation. |
Prognosis comparison
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
- Outcome
- Chronic endocrine condition; course depends on blood-pressure control and hormone management. Exact outcomes are not established.
- Factors
- Severity, associated hormone imbalance, treatment access, and monitoring.
12q14 Microdeletion Syndrome C4305140
- Outcome
- Chronic genetic condition with variable developmental impact; precise prognosis is not established.
- Factors
- Deletion extent, associated findings, developmental support, and comorbidities.
Time frame: Lifelong, with individual variation.
Available evidence does not support exact survival, prevalence, or outcome estimates.
Complications comparison
| Complication | Presentation |
|---|---|
| Blood-pressure-related harm | Elevated blood pressure may cause complications if inadequately managed. Not established as a typical complication in the source description. Specific complication rates are not provided. |
| Reproductive or pubertal effects | Low sex hormones may affect puberty and fertility; extent varies. Reproductive effects are not established by the supplied description. Counseling should be individualized. |
| Neurodevelopmental difficulty | Not described as the principal complication. Learning and developmental difficulties may require ongoing support. Severity and associated anomalies are variable and not fully specified. |
Patient education highlights
- HighSpecialist follow-up
Both are rare chronic conditions; endocrine or genetics specialists should guide testing and care.
- MediumTests versus diagnosis
An abnormal laboratory or genetic result needs clinical correlation and does not automatically confirm the condition.
- MediumTransmission
Neither condition is communicable. Inheritance counseling differs and should be individualized.